Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Epigenic Therapeutics

Company Type: Therapeutic development

Main focus: Developing novel treatments through regulation of the epigenome

Company stage: Pre-clinical

Diseases: Metabolic/liver disease, ophthalmology disorders, central nervous system disorders, cancer

Genome-editing tool: EPIREG® optimised CRISPR-Cas

Funding stage: Series A

Location: Basheng Road, Shanghai, China

Website: https://www.epigenictx.com/

Pipeline: https://www.epigenictx.com/innovation/pipeline

Partners:

Epigenic Therapeutics is a biotech company focused on epigenome-based therapies. Its proprietary EPIREG® platform harnesses advanced CRISPR-Cas systems to regulate gene expression without altering DNA sequences, a technique that aims to address various diseases including metabolic disorders, cancer and chronic viral infections. Using a lipid nanoparticle-based delivery system, Epigenic Therapeutics aims to develop novel treatments with precise targeting, and has shown promising results in pre-clinical models, e.g., in chronic hepatitis B virus (HBV).

Tags

HashtagEpigenic Therapeutics

Company: Epigenic Therapeutics
close
Search CRISPR Medicine